Oric Pharmaceuticals (ORIC) 2024 Wells Fargo Healthcare Conference summary

Company overview and strategy

• Focused on overcoming resistance in cancer, targeting prostate, lung, and breast cancers with a two-pronged approach: internal R&D and opportunistic business development.

• Two lead clinical programs: ORIC-114 (EGFR/HER2 exon 20 inhibitor) and ORIC-944 (allosteric PRC2 inhibitor for prostate cancer).

• Pipeline prioritization is based on strategic fit and market opportunity, with ongoing evaluation of new in-licensing opportunities.

• Business development remains active, but new assets must meet high scientific and strategic standards.

ORIC-114 clinical program updates

• ORIC-114 is brain-penetrant and designed for EGFR/HER2 exon 20 mutations, with unique inclusion of patients with prior exon 20 inhibitor treatment and active brain metastases.

• Initial ESMO data showed confirmed systemic and brain responses, including in patients who failed approved therapies.

• Expansion cohorts for EGFR exon 20, HER2 exon 20, and atypical EGFR mutations are enrolling; data update expected in the first half of next year.

• Two provisional phase II doses (80mg and 120mg) selected; registrational study could start in the second half of next year, with potential for accelerated approval.

• Differentiation based on safety and CNS activity, addressing a significant unmet need in patients with brain metastases.

ORIC-944 clinical program and competitive landscape

• ORIC-944 targets the PRC2 complex, aiming to overcome resistance to AR inhibitors in prostate cancer.

• Early phase I data showed strong drug properties, long half-life, no CYP autoinduction, and good safety profile.

• Moving into combination studies with AR inhibitors (apalutamide, darolutamide), with flexibility to include enzalutamide.

• Pfizer’s mevorametostat data in combination with AR inhibitors is seen as validating for the field; ORIC-944 is positioned as competitive or potentially superior preclinically.

• Prostate cancer remains the primary focus, but other tumor types are being evaluated for future expansion.